Yudai Shinohara

Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer

Akitaka Makiyama, Kohei Arimizu, Gen Hirano et al. · Gastric Cancer · 2017 · 56 citations · Full text

Irinotecan Monotherapy, Surgical Oncology, Gastrointestinal Oncology +9

Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer

Kotoe Takayoshi, Hitoshi Kusaba, Masato Uenomachi et al. · Cancer Chemotherapy and Pharmacology · 2017 · 31 citations · Full text

Oncology, Gastrointestinal Oncology, Cancer Management +5

Predictive impact of C-reactive protein to albumin ratio for recurrent or metastatic head and neck squamous cell carcinoma receiving nivolumab

Kenro Tanoue, Shingo Tamura, Hitoshi Kusaba et al. · Scientific Reports · 2021 · 31 citations · Full text

Spatial dynamics of CD39+CD8+ exhausted T cell reveal tertiary lymphoid structures-mediated response to PD-1 blockade in esophageal cancer

Kenro Tanoue, Hirofumi Ohmura, Koki Uehara et al. · Nature Communications · 2024 · 21 citations · Full text

C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel

Tsuyoshi Shirakawa, Akitaka Makiyama, Mototsugu Shimokawa et al. · Scientific Reports · 2023 · 16 citations · Full text